These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma. LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219 [TBL] [Abstract][Full Text] [Related]
6. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698 [TBL] [Abstract][Full Text] [Related]
7. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer. Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916 [TBL] [Abstract][Full Text] [Related]
8. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics. Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548 [TBL] [Abstract][Full Text] [Related]
9. Metabonomic alterations from pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma facilitate the identification of biomarkers in serum for early diagnosis of pancreatic cancer. Lin X; Zhan B; Wen S; Li Z; Huang H; Feng J Mol Biosyst; 2016 Aug; 12(9):2883-92. PubMed ID: 27400832 [TBL] [Abstract][Full Text] [Related]
10. Study of the metabolomics characteristics of patients with metabolic syndrome based on liquid chromatography quadrupole time-of-flight mass spectrometry. Wu N; Wang W; Yi M; Cheng S; Wang D Ann Endocrinol (Paris); 2018 Feb; 79(1):37-44. PubMed ID: 29246383 [TBL] [Abstract][Full Text] [Related]
11. Two different types of diabetes mellitus in pancreatic cancer population. Comparative study between new onset and long standing diabetes mellitus on 76 patients with pancreatic cancer. Tanţău A; Negrean V; Alexescu T; Para I; Tărmure S; Casoinic F; Sâmpelean D; Mocanu T; Tanţău M Rom J Intern Med; 2014; 52(1):18-23. PubMed ID: 25000673 [TBL] [Abstract][Full Text] [Related]
12. Value of Early Check-Up of Carbohydrate Antigen 19-9 Levels for Pancreatic Cancer Screening in Asymptomatic New-Onset Diabetic Patients. Choe JW; Kim JS; Kim HJ; Hwang SY; Joo MK; Lee BJ; Kim JH; Yeon JE; Park JJ; Byun KS; Bak YT Pancreas; 2016; 45(5):730-4. PubMed ID: 26646277 [TBL] [Abstract][Full Text] [Related]
13. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. Ritchie SA; Akita H; Takemasa I; Eguchi H; Pastural E; Nagano H; Monden M; Doki Y; Mori M; Jin W; Sajobi TT; Jayasinghe D; Chitou B; Yamazaki Y; White T; Goodenowe DB BMC Cancer; 2013 Sep; 13():416. PubMed ID: 24024929 [TBL] [Abstract][Full Text] [Related]
14. Metabolomics identified new biomarkers for the precise diagnosis of pancreatic cancer and associated tissue metastasis. Luo X; Liu J; Wang H; Lu H Pharmacol Res; 2020 Jun; 156():104805. PubMed ID: 32278036 [TBL] [Abstract][Full Text] [Related]
15. A novel serum metabolomics-based diagnostic approach to pancreatic cancer. Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803 [TBL] [Abstract][Full Text] [Related]
16. [Metabolomics study of Danggui Buxue Tang on treatment of type 2 diabetes mice using UHPLC-Q-TOF-MS]. Sun LL; Bai HY; Zheng WH; Wang LY; Zhao W; Li JY; Shi YB; Yang ZG Zhongguo Zhong Yao Za Zhi; 2020 Feb; 45(3):636-644. PubMed ID: 32237524 [TBL] [Abstract][Full Text] [Related]
17. Predictive Factors for Differentiating Pancreatic Cancer-Associated Diabetes Mellitus from Common Type 2 Diabetes Mellitus for the Early Detection of Pancreatic Cancer. Dong X; Lou YB; Mu YC; Kang MX; Wu YL Digestion; 2018; 98(4):209-216. PubMed ID: 30045045 [TBL] [Abstract][Full Text] [Related]
18. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer. Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754 [TBL] [Abstract][Full Text] [Related]
19. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer. Xiong Y; Shi C; Zhong F; Liu X; Yang P Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985 [TBL] [Abstract][Full Text] [Related]
20. Pancreatic cancer screening using a multiplatform human serum metabolomics system. Sakai A; Suzuki M; Kobayashi T; Nishiumi S; Yamanaka K; Hirata Y; Nakagawa T; Azuma T; Yoshida M Biomark Med; 2016 Jun; 10(6):577-86. PubMed ID: 27171159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]